Neuroendocrine Tumors
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumors.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-25Clinical Trial Results: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors [Phase 2]
Phase 2 trial results for nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lun…
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas [Phase 2, Phase 3]
A Phase 2/Phase 3 trial evaluating Sandostatin LAR plus Axitinib versus placebo in patients with advanced well-differentiated non-pancreatic…
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Results: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas [Phase 2, Phase 3]
A completed phase 2/3 trial evaluating Sandostatin LAR plus axitinib versus placebo in patients with advanced well-differentiated non-pancre…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours [Phase 1]
Phase 1 trial update evaluating the combination of 177Lu-DOTA-TATE with Olaparib in somatostatin receptor-positive tumors has completed. The…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients [Phase 3]
Phase 3 trial update evaluating the efficacy and safety of 177Lu-edotreotide peptide receptor radionuclide therapy in gastroenteropancreatic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Entinostat Neuroendocrine (NE) Tumor [Phase 2]
Phase 2 trial of entinostat in neuroendocrine tumors was terminated. Results were posted on 2026-03-02.
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer [Phase 2]
Phase 2 trial of pembrolizumab plus lenvatinib in advanced/metastatic neuroendocrine prostate cancer; results were posted in February 2026.
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: 18F-DOPA II - PET Imaging Optimization [Phase 3]
Phase 3 trial of the imaging agent 18F-DOPA II for PET imaging optimization is currently recruiting, sponsored by the University of Alberta,…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Post-Authorization Long-Term Safety Study of LUTATHERA
Update on the post-authorization long-term safety study of LUTATHERA for neuroendocrine tumors, with study status listed as ACTIVE_NOT_RECRU…
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors [NA]
Clinical trial update on Lu-DOTATATE treatment for somatostatin receptor–positive neuroendocrine tumors; the study is currently active but n…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents [NA]
A completed clinical trial evaluating MGMT enzyme status as a predictive factor for response to alkylating agents in neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: EchoTip AcuCore Post-Market Clinical Study
Completed post-market clinical study update for the EchoTip AcuCore device, detailing the completion of the post-market evaluation.
-
CLINICAL_TRIALS trial_result · 2025-09-16Clinical Trial Update: Open-label Study of Surufatinib in Japanese Patients [Phase 1, Phase 2]
Open-label Phase 1/Phase 2 study of Surufatinib in Japanese patients with Neuroendocrine Tumors has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies [Phase 1]
Ongoing Phase 1 safety/efficacy trial of CID-078 in patients with advanced/metastatic solid tumors; study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-07-14Clinical Trial Update: Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors [EARLY_Phase 1]
An EARLY Phase 1 clinical trial of Gallium-68 Pentixafor for neuroendocrine tumors is listed as active but not currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers [Phase 2]
Phase 2 study evaluating adoptive transfer of tumor-infiltrating lymphocytes (TIL) for advanced solid cancers, with multiple site-specific i…
-
CLINICAL_TRIALS trial_result · 2025-06-25Clinical Trial Update: Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors
This document reports the completion of a clinical trial evaluating whole-body dynamic PET/CT imaging with 68Ga-DOTATOC in neuroendocrine tu…
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients [Phase 2]
Phase 2 trial comparing 177Lu-Dotatate with capecitabine vs 177Lu-Dotatate alone in neuroendocrine tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-05-09Clinical Trial Update: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide [Phase 4]
Phase 4 trial comparing patient experience on octreotide long-acting release versus lanreotide in neuroendocrine tumor patients; results hav…
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors [Phase 1, Phase 2]
The Phase 1/2 trial of surufatinib in combination with tislelizumab for advanced solid tumors has been terminated. Results were posted on 20…
-
CLINICAL_TRIALS trial_result · 2025-04-17Clinical Trial Update: A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors [Phase 1]
Phase 1 trial of Pelcitoclax (APG-1252) for Neuroendocrine Tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies [Phase 1, Phase 2]
Memorial Sloan Kettering Cancer Center completed a Phase 1/Phase 2 clinical trial evaluating the 18F-MFBG imaging agent for evaluating neuro…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) [Phase 2]
A Phase 2 trial (QUADRUPLE THREAT) evaluated RRx-001 in small cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and epith…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors [Phase 2]
Phase 2 clinical trial updating the validation of 99mTc-EDDA-HYNIC-TOC diagnostic kits for neuroendocrine tumors (completed).
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: The Role of Intraoperative Hepatic Ultrasonography in Gastrointestinal or Pancreatic Neuroendocrine Tumor
This clinical trial update discusses the use of intraoperative hepatic ultrasonography during surgery for gastrointestinal or pancreatic neu…